Evidence map›Paper›PMID 30659903›Full record

Observational studyUrology2019

Use of MRI-Guided Biopsy for Selection and Follow-up of Men Undergoing Hemi-gland Cryoablation of Prostate Cancer.

Steve R Zhou, Demetrios N Simopoulos, Rajiv Jayadevan, Ely R Felker, Merdie K Delfin, Danielle E Barsa, Lorna Kwan, Leonard S Marks

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Steve R ZhouDavid Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
Demetrios N SimopoulosDepartment of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
Rajiv JayadevanDepartment of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
Ely R FelkerDepartment of Radiology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
Merdie K DelfinDepartment of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
Danielle E BarsaDepartment of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
Lorna KwanDepartment of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
Leonard S MarksDepartment of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA. Electronic address: lsmarks@ucla.edu.
University of California, Los Angeles · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the ProstateR01CA158627 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARKS, LEONARD STEPHEN · 2011 to 2013
$1.4M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS R01 CA158627
6 · The paper itself

Abstract

objectiveTo investigate safety, efficacy, and quality of life impact of hemi-gland cryotherapy for clinically-significant prostate cancer (CaP), when patient selection and follow-up includes MRI-guided biopsy.

methodsTwenty-nine men with unilateral CaP (all clinically significant with prostate volume <60 cc) were enrolled in a prospective observational trial of hemi-gland cryotherapy. Mean patient age was 68.7 years. Median prostate-specific antigen (PSA) was 6.6 ng/mL. MRI-guided biopsy (3T-MRI, Artemis US fusion) was used for diagnosis and repeated at 6-month follow-up in all men. Treatment was under general anesthesia using the BTG/Galil system. Validated questionnaires were used to determine effects of treatment on urinary and sexual function and quality of life.

resultsCryotherapy was completed satisfactorily in all 29 cases in <60 minutes with no intraoperative complications. Significant decreases in PSA (median decrease 5.6 ng/mL) and PSA density (median decrease 0.14 ng/mL/cc) were observed (P < .01). At 6 months, 23 patients (79%) demonstrated no residual cancer on follow-up MRI-guided biopsy of the treated side. Three patients (10%) revealed micro-residual disease. Three patients (10%) had residual cancer and underwent further treatment. Ipsilateral MRI lesions were present before treatment in 26 patients and after treatment in only 2, reflecting the gross ablative effect; however, MRI showed disappearance of lesions in 4 patients with residual tumor on biopsy. The single complication was 1 case of transient urinary retention; 85% of men who were sexually active continued without change after treatment. Voiding function was unchanged.

conclusionHemi-gland cryoablation for clinically-significant CaP is well-tolerated, and when patients are selected and followed by MRI/US fusion biopsy, cancer control appears promising at 6 months.

Indexed as

CryosurgeryMagnetic Resonance ImagingAgedFollow-Up StudiesHumansImage-Guided BiopsyMalePatient SelectionProspective StudiesProstatic NeoplasmsQuality of LifeTreatment Outcome

Identifiers

PMID30659903
PMCPMC6698362
OpenAlexW2909655401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.